Lutetium Lu-177 PSMA-R2 is a radioconjugate composed of PSMA-R2, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. The directory classifies it as a clinical API with a peptide source/manufacturing origin. Other names for this substance include 177LUPSMA-R2 and A9QKN9CW96. Its PubChem CID is 172866254.
Lutetium LU-177 psma-R2
| CAS No | 2579082-09-8 |
|---|---|
| Molecular Formula | C41H60BrLuN8O15 |
| Molecular Weight | 1161.80 g/mol |
| Synonyms | 2-[4-[2-[[6-[(4-bromophenyl)methyl-[(5S)-5-carboxy-5-[[(1S)-1,3-dicarboxypropyl]carbamoylamino]pentyl]amino]-6-oxohexyl]amino]-2-oxoethyl]-7,10-bis(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;lutetium-177(3+) |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Lutetium Lu-177 PSMA-R2 is a radioconjugate composed of PSMA-R2, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells.
The listed CAS number is 2579082-09-8.
The listed molecular formula is C41H60BrLuN8O15.
The listed molecular weight is 1161.80 g/mol.
2-[4-[2-[[6-[(4-bromophenyl)methyl-[(5S)-5-carboxy-5-[[(1S)-1,3-dicarboxypropyl]carbamoylamino]pentyl]amino]-6-oxohexyl]amino]-2-oxoethyl]-7,10-bis(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;lutetium-177(3+).
The source lists 177LUPSMA-R2 and A9QKN9CW96.